Abstract
Genetic mutations that yield defective cystic fibrosis transmembrane regulator (CFTR) protein cause cystic fibrosis, a life-limiting autosomal recessive Mendelian disorder. A protective role of CFTR loss-of-function mutations in inflammatory bowel disease (IBD) has been suggested, but its evidence has been inconclusive and contradictory. Here, leveraging the largest IBD exome sequencing dataset to date, comprising 38,558 cases and 66,945 controls in the discovery stage, and 35,797 cases and 179,942 controls in the replication stage, we established a protective role of CF-risk variants against IBD based on evidence from the association test of CFTR delF508 (p-value=8.96E-11) and the gene-based burden test of CF-risk variants (p-value=3.9E-07). Furthermore, we assessed variant prioritization methods, including AlphaMissense, using clinically annotated CF-risk variants as the gold standard. Our findings highlight the critical and unmet need for effective variant prioritization in gene-based burden tests.
Competing Interest Statement
M.J.D. is a founder of Maze Therapeutics. C.A.A. has received consultancy fees from Genomics plc and BridgeBio Inc. and lecture fees from GSK. The remaining authors declare no competing interests.
Funding Statement
We thank all of the principal investigators, local staff from individual cohorts, and all of the patients who kindly donated samples used in the study for making possible this global collaboration and resource to advance IBD genetics research. This research was funded in whole, or in part, by the US National Institutes of Health grants no. U54HG003067 and no. 5UM1HG008895, the Wellcome Trust grants no. [206194] and no. [108413/A/15/D], and The Leona M. & Harry B. Helmsley Charitable Trust grant no. 2015PG-IBD001. We thank the Broad Institute Genomics Platform for genomic data generation efforts and the Stanley Center for Psychiatric Research at the Broad Institute for supporting control sample aggregation. We thank the Sanger Institute Scientific Operations teams and Human Genetics Informatics team for sample handling and data generation. This research was supported by the NIHR IBD BioResource and NIHR Biomedical Research Centres in Cambridge, Oxford, Imperial, UCH and Newcastle. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. The NIHR IBD BioResource acknowledges co-funding by Crohns Colitis UK and The Leona M. and Harry B. Helmsley Charitable Trust. H.H. acknowledges support from NIDDK grant no. R01DK129364 and the Stanley Center for Psychiatric Research. Individual studies contributing to this project acknowledge support from NIH grants no. DK062431, no. DK062432, no. DK087694, no. K23DK117054, no. R01DK111843, no. P01DK094779, no. R01HG010140, no. 5U01HG009080 and no. DK062420, and NIDDK grants no. P01DK046763, no. U01DK062413, DK 043351 and no. R01DK104844.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethical guidelines have been followed, and any necessary institutional review board (IRB) and/or ethics committee approvals have been obtained. The Broad Institute component of this study was approved under Study Protocol 2013P002634 (the Broad Institute Study of Inflammatory Bowel Disease Genetics), and undergoes annual continuing review by the Mass General Brigham Human Research Committee IRB of Mass General Brigham (Mass General Brigham IRB). Approval was given on 27 January 2021 for this study. DNA samples sequenced at the Sanger Institute were ascertained under the following ethical approvals: 12/EE/0482, 12/YH/0172, 16/YH/0247, 09/H1204/30, 17/EE/0265, 16/WM/0152, 09/H0504/125, 15/EE/0286, 11/YH/0020, 09/H0717/4, REC 22/02, 03/5/012, 03/5/012, 2000/4/192, 05/Q1407/274, 05/Q0502/127, 08/ H0802/147, LREC/2002/6/18, GREC/03/0273 and YREC/P12/0. All informed consent from participants has been obtained, and the appropriate institutional forms have been archived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* These authors jointly supervised this work. Emails: ca3{at}sanger.ac.uk, mjdaly{at}broadinstitute.org, hhuang{at}broadinstitute.org
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.